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Effect of physical therapy on joint range of motion 
and muscle collagen deposition in the golden 
retriever muscular dystrophy (GRMD) model
Efeito da fisioterapia na amplitude de movimento articular e deposição de 
colágeno muscular no modelo golden retriever muscular dystrophy (GRMD)
Gaiad TP1, Miglino MA1, Zatz M2, Hamlett WC3, Ambrosio CE1
Abstract
Objective: To elucidate the effect of physical therapy on joint range of motion (ROM) and muscle fibrosis in GRMD animals. Methods: 
This was a nonrandomized blinded study with a control group, with six months of intervention evaluated beforehand and afterwards. Six 
dystrophic male Golden Retrievers of mean age 10.16±3.46 months and weight 17.75±6.01 kg were divided into a treated group (n=3) 
and an untreated group. These groups of dogs were named: G1=treated group before treatment; G2=treated group after treatment; 
G3=untreated group before treatment; and G4=untreated group after treatment. G1 underwent a physical therapy program that 
consisted of a 300-meter circuit with obstacles. Stifle, tarsal, elbow and carpal ROM were assessed using a goniometer before and after 
treatment. The area of collagen in the vastus lateralis muscle was measured using histomorphometry. The locations of collagen types 
I, III and IV were studied using immunohistochemistry. Results: The tarsal ROM values in G2 presented an increasing trend. The area 
of muscle collagen differed between the groups after treatment and an increasing trend in these values was observed in G4. Collagen 
types I and III were the ones most frequently observed, forming broad bands in the perimysium of both G2 and G4. Type I collagen was 
observed in the endomysium more than type III collagen. Type IV collagen was observed only in the basal layer. Conclusion: Physical 
Therapy seemed to improve tarsal ROM in the treated group without increasing muscular fibrosis. 
Key words: muscular dystrophy; collagen; joints; physical therapy; animal model.
Resumo
Objetivo: Elucidar o efeito da fisioterapia na Amplitude de Movimento Articular (ADM) e na fibrose muscular em animais GRMD. Métodos: 
Estudo não randomizado, com grupo controle, cego, seis meses de intervenção, avaliação antes e depois da intervenção. Seis animais 
da raça Golden Retriever, distróficos, machos, média de idade 10,16±3,46 meses e peso de 17,75±6,01 kg foram separados em grupo 
tratado (n=3) e não tratado. Esses grupos de animais foram nomeados: G1=grupo tratado antes do tratamento; G2=grupo tratado 
após tratamento; G3=grupo não tratado antes do tratamento; G4=grupo não tratado após tratamento. O G1 participou do programa de 
fisioterapia que consistiu em um circuito de 300 metros com obstáculos. As ADMs do joelho, tarso, cotovelo e carpo foram avaliadas 
com goniômetro antes e após o tratamento. A área de colágeno do músculo vastus lateralis foi mensurada por histomorfometria, e a 
localização dos tipos de colágeno I, III e IV foi estudada por Imuno-histoquímica (IHC). Resultados: Os valores da ADM do tarso do 
G2 apresentaram uma tendência a aumentar. A área de colágeno muscular foi diferente entre os grupos após o tratamento, e uma 
tendência ao aumento desses valores no G4 foi observada. Os colágenos dos tipos I e III foram os mais observados, constituindo 
feixes largos no perimísio nos dois grupos (G2 e G4). O colágeno do tipo I foi mais observado no endomísio do que o colágeno do 
tipo III. O colágeno do tipo IV foi observado apenas na lâmina basal. Conclusão: A Fisioterapia parece aumentar a ADM do tarso dos 
animais do grupo tratado sem aumentar a fibrose muscular.
Palavras-chave: distrofia muscular; colágeno; articulações; fisioterapia; modelo animal.
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Introduction 
Lack of dystrophin protein in muscle cells is characteristic 
of duchenne muscular dystrophy (DMD), which is a progres-
sive and fatal X-linked genetic disorder. Animal models have 
been studied to identify efficient treatments for this disease 
in humans1.
The golden retriever muscular dystrophy (GRMD) model 
has been widely studied2, since it presents muscle abnormali-
ties that are closest to the ones seen in humans: increased cre-
atine kinase (CK) activity, muscle hypotrophy associated with 
contractures, muscle necrosis, degeneration, endomysial and 
perimysial fibrosis and cardiomyopathy3.
So far, no treatment to stop DMD progression has been 
found. Physical therapy has been used to reduce the muscu-
lar, skeletal, cardiac and vascular abnormalities that develop 
in association with muscle strength loss. The main objective 
in such therapy is to prevent muscle contractures and bone 
deformities4.
Studies on physical therapy interventions on the GRMD 
model are scarce. Among humans, physiotherapeutic 
methods have yielded controversial results5. Some of these 
methods have suggested that DMD patients should perform 
moderate exercises6, while others have suggested that these 
patients should undertake recreational activities and activi-
ties of daily living7,8. However, few studies have actually as-
sessed benefits9,10.
According to Grange and Call11, the same exercise used to 
increase muscle strength and endurance in normal individu-
als can exacerbate muscle damage in a dystrophic muscle. The 
authors suggested that a threshold must be defined to guide 
suitable exercise prescription for DMD patients. Kimura et al.12, 
however, showed that immobility could reduce muscle fiber 
necrosis in muscular dystrophy cases.
Different types of exercise prescriptions have been well 
defined in the dystrophic mouse model5,11,13. In contrast, this 
model presents significant differences regarding the amount 
of muscle mass and the characteristics of its clinical progres-
sion that make it difficult to directly apply these results to 
humans1.
Assessment of passive joint mobility is an indicator of 
muscle flexibility and contracture. Its use in some studies on 
dogs has been described14,15 to aid in making decisions on ap-
propriate therapeutic interventions and to document the ef-
fectiveness of these interventions.
According to Valentine et al.16, progressive endomysial and 
perimysial fibrosis is a common characteristic in DMD patients 
and in the GRMD model, but it is not observed in the dystro-
phic mouse model. They suggested that increased interstitial 
collagen levels could interfere with normal muscle metabolism, 
thereby leading to abnormal regeneration, decreased vascular 
perfusion and mechanical restrictions.
Dystrophic muscle tissue presents abnormally increased 
muscle collagen fibers due to repeated degeneration and 
regeneration of dystrophin-deficient muscle tissue. Some 
studies have reported that collagen fiber types I, III and IV 
are present, in increased proportions, in muscular dystro-
phy cases17-19.
Considering that GRMD presents progressive mobility re-
striction and muscle fibrosis due to repeated muscle lesions, 
the aim of the present study was to elucidate the effect of 
motor physical therapy on passive joint mobility and muscle 
morphology among GRMD dogs.
Methods 
Animals
Six dystrophic male Golden Retrievers were selected 
from the GRMD-Brazil kennel of the Anatomy Sector, De-
partment of Surgery, Universidade de São Paulo (USP). The 
Human Genome Center, Institute of Biology, USP, had previ-
ously used DNA analysis on blood samples from these dogs, 
taken between the first and third day of life, to confirm the 
presence of muscular dystrophy. This research was approved 
by the Bioethics Commission of the School of Veterinary 
Medicine and Animal Science, USP, under protocol number 
900/2006.
Study design 
The GRMD animals were separated into two groups: 
treated and untreated, according to biometric data. One group 
of three dogs received physical therapy (treated group) and 
the remaining three dogs (untreated group) did not receive 
any treatment. The groups were analyzed before and after the 
time of treatment, thus, for analysis, they were subdivided into: 
G1 =  treated group before treatment; G2 = treated group after 
treatment; G3 = untreated group before treatment; G4 = un-
treated group after treatment. 
No statistical difference between G1 and G3 was observed 
with regard to the mean weights and ages (Table 1). After the 
first range of motion (ROM) evaluation and muscle biopsy col-
lection, G1 underwent the physical therapy protocol. 
G3 continued to follow the same routine of kennel life. An 
open-air enclosure of 20 m2 in area was available during the 
day, while at night, the dogs were kept in closed pens of 1 to 
3 m2 in area. Daily activities consisted of feeding, cleaning care 
and clinical analysis. 
ROM and muscle collagen in GRMD model undergoing physical therapy
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therapy sessions (Figure 1). One half was composed of grass 
and contained four obstacles. The obstacles consisted of, in 
order: a bar that the dogs were required to go under; a ser-
pentine course around two cones; a 10 cm hurdle that they 
were required to go over; and a similar 20 cm hurdle. All the 
obstacles required head, trunk and limb flexion. The other 
half of the course was concrete and contained no obstacles. 
The dogs were required to complete five circuits of the course, 
making a total of 300 m. At the end of the 300 meters, they 
rested comfortably on their sides. If they were seen to present 
halting gait and increased respiration, they were allowed to 
rest briefly before completing the circuit. 
Outcome measurements
Outcomes were measured in terms of the ROM of the el-
bow, carpal, stifle and tarsal joints and the area of collagen 
on the vastus lateralis muscle in relation to the total area of 
muscle tissue, before and after the intervention program. 
After treatment, muscle collagen types I, III and IV were as-
sessed using immunohistochemical techniques to make in-
ferences about the adaptations of the dystrophic muscle due 
to fibrosis.
Joint range of motion (ROM)
Flexion and extension joint ROM data were collected using 
a manual universal goniometer with 2º gradations. During data 
collection, the dogs did not receive any sedation, in order to 
allow normal expression of pain due to over-extension or over-
flexion of joints.
They were comfortably positioned in lateral recumbence. 
Considering that no standard measurements of the anatomical 
joint positions for the Golden Retriever breed exist, we estab-
lished a joint ROM assessment through the complete extent of 
flexion and extension, as described by Jaegger, Marcellin-Little 
and Levine22 in Labrador Retrievers.
Measurements were made while keeping the dog’s joints 
moving slowly and continuously to avoid muscle stretch re-
sistance. Maximum flexion and extension were determined 
by the endurance that the animals presented at the end of the 
ROM and any pain signals such as contralateral limb move-
ments of discomfort.
The center of the goniometer was positioned on each 
joint axis during the measurements. The proximal and dis-
tal arms of the goniometer were positioned on selected ana-
tomical landmarks of the limbs, in accordance with Jaegger, 
Marcellin-Little and Levine22. Three consecutive measure-
ments were made, and the mean value and standard devia-
tion were calculated.
G1: treated group before treatment; G3: untreated group before treatment; t test comparing 
groups, p<0.05.
Groups Animal identification Age (months) Weight (kg)
G1 BI1M4 9 18.5
BR3M5 13 21.2
CH1M3 6 18
G1 (mean value±SD) 9.66±3.51 19.23±1.72
G3 BR3M7 13 13.5
BR3M2 13 22
CH1M5 6 20
G3 (mean value±SD) 10.67±4.04 18.5±4.44
p value 0.354 0.401
Table 1. Biometric features of the GRMD dogs in groups G1 and G3.
Intervention
The type, frequency and duration of the exercise protocol 
were selected based on the published recommendations for DMD 
patients6-8,20,21 and on field research by the Brazilian Association for 
Muscular Dystrophy (ABDIM). The motor physical therapy ses-
sions were administered three times a week for 45 minutes to each 
animal, for six months. The physical therapy program consisted of 
a free walking activity with the objectives of maintaining the ROM 
and functional activities of the affected dogs, as well as preventing 
cardiac, pulmonary and skeletal complications.
An oval area with diameters of 30 x 5 meters and a to-
tal length track of 60 meters was constructed for physical 
Figure 1. Physical therapy protocol and obstacles. 
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1: going under a bar; 2: serpentine course around two cones; 3: going over a 10 cm hurdle; 
4: going over a 20 cm hurdle; 5: walking on the cement; 6: returning to the grass.
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Muscle biopsy
Muscle fragments were collected from the vastus lateralis 
muscle of each dog, before and after treatment. To avoid any 
loss of motor function in these GRMD animals, a single muscle 
was chosen to represent the pelvic limb. The hind limbs are 
considered more affected in the canine dystrophy model3, and 
the vastus lateralis was described by Childers et al.23 as a muscle 
group that incurs damage and regeneration between the ages 
of one and six months in GRMD dogs. 
An open biopsy was performed and a 1 cm2 fragment was 
collected from the middle portion of the muscle. After ve-
nous cannulation and fluid therapy, the dogs were subjected 
to an anesthetic protocol: acepromazine maleate (Acepran, 
Laboratório Univet S/A., Brazil) and tramadol hydrochloride 
(Tramal, Laboratório Pfizer Ltda, Brazil) (0.05 mg/km and 
2 mg/kg, respectively), intramuscularly. The skin incision, sub-
cutaneous tissue and muscle fascia received local infiltrative 
anesthesia consisting of lidocaine hydrochloride 2% (Lidol 2%, 
Hipolabor Farmacêutica Ltda., Brazil) without vasoconstric-
tor (7 mg/ kg). Propofol (propofol, Laboratório Eurofarma, 
Brazil) (2.5 mg/ kg) was administered intravenously prior to 
muscle biopsy. Intravenous ketoprofen (ketoprofen, Labo-
ratório Merial, Brazil) (1 mg/kg) was used postoperatively. 
Analgesia using the same drugs was administered orally for 
3 to 5 days afterwards. Cephalexin (Keflex, Antibióticos do 
Brasil Ltda., Brazil) was used for antibiotic therapy (20 mg/kg 
BID), for seven days. The biopsies before and after treatment 
were performed around the scar tissue in order to avoid scar 
fibrosis in the muscle fragments.
Muscle collagen quantification 
Muscle fragments were cooled using liquid nitrogen and 
were frozen at -80ºC. Cross-sections of 6 to 8 µm in thickness 
were made using a Leica Cryostat CM 1850 at -20ºC. The cross-
sections were stained using picrosirius red in order to distin-
guish collagen from skeletal muscle. Picrosirius is a solution 
of sirius red and picric acid that stains collagen fibers red and 
muscle tissue yellow. 
To accurately quantify collagen-positive areas, slides from 
thirty randomly selected low-power fields per muscle section 
from each dog were viewed under a microscope (Axioplan 2; 
Carl Zeiss, Inc.). Digital images were captured on a video ar-
chival system using a digital TV camera system (AxioCam 
high-resolution color, Carl Zeiss, Inc.). An automated software 
analysis program (KS400, Carl Zeiss, Inc.) was used to deter-
mine the percentage of stained areas on the digital photomi-
crographs, in accordance with Sato et al.24.
The area of collagen was measured in µm2. The mean values 
and standard deviations from the thirty fields from each ani-
mal were converted into percentages of the total muscle area. 
Immunohistochemistry
Sections were stained for collagen types I, III and IV. Pri-
mary mouse anti-collagen types I and III (Calbiochem) and 
goat anti-collagen type IV (Bioreagents) were applied, sepa-
rately. The primary antibody dilutions were: collagen type I, 
1:500; collagen type III, 1:750; and collagen type IV, 1:250). After 
being washed three times in phosphate-buffered saline (PBS), 
the sections were incubated for 45 minutes with secondary bi-
otinylated antibody (Dako Ltd.) in a damp chamber at room 
temperature. After three more rinses in PBS, streptavidin was 
applied for 45 minutes. The sections were washed with PBS and 
covered with DAB for 1 to 2 minutes. They were then mounted 
using Paramount, and photomicrographs were made using an 
optical microscope (Axioscope, Zeiss) and an Olympus BX 60 
camera. All the incubations were performed in a damp cham-
ber at room temperature. On control sections, the primary 
antibody was omitted.
Statistical analysis
The mean values for joint ROM and area of collagen in the 
muscles of the GRMD dogs, between the treated and untreated 
groups, were compared using the t test. Before and after-treat-
ment values were compared using the paired t test. The values 
were analyzed and considered statistically different when the 
p-value was <0.05. 
Results 
ROM measurements were made in all groups. No significant 
difference was observed in tarsal ROM measurement between 
G1 and G3 (p=0.419). After treatment, there was statistical 
difference in tarsal ROM measurement between the groups 
(comparison between G2 and G4, p=0.040), and G2 presented a 
trend towards tarsal ROM increase (Table 2). The mean elbow 
ROM values between G1 and G3 were not statistically different 
before the treatment (p=0.227) and maintained this character-
istic during the study period (p=0.500). The carpal ROM of both 
GRMD groups was hyperflexed before and after treatment. The 
mean ROM values of the two GRMD groups before (G1 and 
G3) and after six months of intervention (G2 and G4) were not 
statistically different for all the joints evaluated.
The mean area of the collagen bundles in healthy muscle 
was 1.69% of the total muscle area (603.126 µm2) and was lower 
ROM and muscle collagen in GRMD model undergoing physical therapy
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than the mean value for the six GRMD dogs (6.95%±0.32) before 
treatment. There was no difference between G1 (5.53%±1.77) 
and G3 (5.80%±3.57) (p=0.929). After treatment, there was a 
difference between G2 and G4 (p=0.014) (Figure 2).
There was no statistical difference when comparing before 
and after treatment values within the groups. A trend towards 
increased collagen area in G4 was observed, without statistical 
difference (p=0.288) (Table 3). 
In immunohistochemical analysis, the perimysium of all 
animals stained positively for collagen types I and III in en-
larged tracts. The endomysium stained positively for collagen 
type I especially (Figures 3A and B) and for collagen III in thick 
tracts (Figures 3C and D). No significant difference between G2 
and G4 was observed. The basal layer of muscle fibers consist-
ing of thick tracts stained for collagen type IV, thus not differing 
from healthy muscle (Figures 3E and F). 
Table 2. Mean joint range of motion (ROM) data from GRMD dogs before and after treatment (in degrees).
G1 G3 p value G2 G4 p value
Elbow 123.33±5.77 116.67±12.5 0.227 120±5 120±5 0.500
Carpal joint 145±13.2 157.33±4.04 0.017* 145±5 150±5 0.112
Stifle 105.67±6.02 110 0.008* 116.67±7.63 118.33±10.4 0.371
Tarsal joint 115±18.0 116.67±12.5 0.419 141.67±7.63 128.33±12.5 0.040*
G1: treated group before treatment; G2: treated group after treatment; G3: untreated group before treatment; G4: untreated group after treatment. * t test, p value <0.05.
Table 3. Area of collagen deposition in GRMD dogs expressed as 
percentage of the total area (603.126µm2).
Treated (n=3) Untreated (n=3) p value
Before treatment 5.53%±1.76 (G1) 5.80%±3.57 (G3) 0.929*
After treatment 5.58±1.11 (G2) 9.64±1.53 (G4) 0.014*†
p value 0.879** 0.239**
* t test / ** paired t test. † p<0.05. Note: values are expressed as mean±SD.
Figure 3. Photomicrograph of immunohistochemical analysis of 
collagen in skeletal muscle of dystrophic dogs. Positive immunostaining 
for collagen type I, in dogs from G4 (A) and G2 (B); bar=40 µm. 
Positive immunostaining for collagen type III, in dogs from G4 (C) 
and G2 (D), bar=40 µm. Positive immunostaining for collagen type 
IV, in dogs from G4 (E) and G2 (F); bar=20 µm. In A, B, C and D: 
perimysial fibrosis (∗) and endomysial fibrosis (→); in E and F: 
basal layer of muscle fiber (►).
Figure 2. A. Photomicrograph of the vastus lateralis muscle of an 18-
month-old dystrophic dog. Perimysial (→) and endomysial (∗) connective 
tissue, stained with HE. B. Photomicrograph under polarized light of normal 
adult skeletal muscle, stained with picrosirius red. C. Photomicrograph 
under polarized light of dystrophic vastus lateralis muscle in 18-month-old 
untreated dog (G4), stained with picrosirius red. D. Photomicrograph under 
polarized light of dystrophic vastus lateralis muscle in 18-month-old treated 
animal (G2), stained with picrosirius red.
Gaiad TP, Miglino MA, Zatz M, Hamlett WC, Ambrosio CE
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Discussion 
The dogs that underwent physical therapy showed in-
creased tarsal ROM and maintenance of the area of muscle 
collagen. This was not observed in the untreated group. 
Compared with healthy Golden Retrievers, the mean tarsal 
ROM values were found to be limited in dystrophic dogs25. In 
that study, normal dogs showed mean values of 123.57º±8.69 
for the tarsal joint at a mean age of 17 months. 
In another GRMD group, Kornegay et al.26 described tarsal 
ROM in 13 dogs aged three to six months. They observed a 
significant reduction in ROM over this period, with a median 
value of 117º±24.5 at six months of age. There was a decrease in 
tarsal ROM associated with aging beyond six months of age. 
In our group, the main ROM reductions were in the stifle 
and tarsal joints associated with carpal hyperflexion during 
gait in most of the dogs around the age of four months27. This 
situation leads to a characteristic gait, namely plantigrady for 
tarsal ROM and palmigrady for carpal ROM. 
These ROM abnormalities, associated with significant loss 
of muscle mass, change postural conformation and progres-
sively restrict gait. Maintenance of, or increase in, the ROM of 
this joint is not common and may be attributed to physical 
therapy, since it was only observed in the treated group. 
The GRMD dogs in the treated and untreated groups pre-
sented ROM values that suggested carpal joint over-flexion. 
Kornegay et al.26 also found increased values for the carpal 
ROM in GRMD animals. 
Dystrophic animals develop defects in the thoracic limbs 
later than in the pelvic limbs3. Moreover, during quadruped 
posture and gait, the forelimbs carry more body weight than 
the pelvic limbs. Over-flexion of the carpal joint may result 
from overload due to primary changes in the hind limbs, 
such as tarsal and stifle ROM reduction.
The proximal joints, such as the elbow and stifle, seem to 
suffer fewer modifications than the distal joints, such as the 
carpal and tarsal joints. Further follow-up studies on these 
two proximal joints may elucidate their progression in the 
canine muscular dystrophy model.
In association with the ROM abnormalities, these dogs 
showed significant histopathological characteristics of 
dystrophic muscle, particularly endomysial and perimysial 
fibrosis. The histological features of dystrophic muscles 
have been described, including fiber diameter changes, 
necrosis, regeneration, hyalinization and inflammatory 
response16,17,28,29. The common features of progressive en-
domysial and perimysial fibrosis between the GRMD model 
and humans16 make it possible to answer some questions 
using animal models of DMD for further application on hu-
man beings.
The relationship between fibrosis and therapeutic exercise 
in the GRMD model has not been studied yet. It has been found 
that the muscle fibers of dystrophic dogs that reach the degen-
erative stage are gradually replaced by fibrous and adipose con-
nective tissue16.
Before treatment, the dystrophic dogs already presented 
increased areas of collagen on muscle tissue, compared with 
healthy muscle. The difference observed between G2 and G4 
indicated a trend towards connective tissue increase in G4. 
Since G4 did not undergo physical therapy, it is possible that 
the protocol used gave rise to positive adaptations to the mus-
cle morphology of the treated group.
Immobility and dystrophic muscle have been discussed by 
some authors with different conclusions. Kimura et al.12 reported 
the case of a three-year-old boy with a diagnosis of spina bifida 
and DMD. A muscle biopsy on this patient showed that necrosis 
and regeneration of muscle fiber was more prevalent in the biceps 
brachii (with normal movement) than in the gastrocnemius mus-
cle (without movement). This suggests that immobility reduces 
muscle fiber necrosis in dystrophin-deficient muscular dystrophy.
In contrast, Mackey, Donnelly and Roper30 compared 
healthy endurance-trained and inactive individuals and found 
a negative association between aerobic capacity and the colla-
gen-type III and IV content of the endomysium. These results 
suggest that muscle inactivity leads to great deposition of these 
types of collagen.
Collagen fibers are the main component of connective tis-
sue. However, each type of collagen protein is associated with 
certain characteristics of the tissue. Collagen types I and III are 
interstitial proteins found in different proportions in muscle 
tissue according to its function, adaptations or pathological 
conditions. Collagen type I restricts the tissue, while type III is 
observed in tissues that are more flexible. Collagen type IV can 
be found in the basal layer and has a structural function30. For 
this reason, studying the different types of collagen may clarify 
the adaptive mechanisms of dystrophic muscles.
Through immunohistochemical analysis on the locations 
of collagen types, there were greater amounts of collagen types 
I and III in the perimysium. The endomysium stained mainly 
for collagen type I, which suggests less flexibility and restricted 
movement. No visual differences between G2 and G4 were 
observed. A quantitative study is needed for better compre-
hension of the proportions and locations of collagen types in 
dystrophic muscle tissue.
Physical therapy is likely to improve tarsal ROM in the treated 
group without increasing muscle fibrosis. Because muscular 
dystrophy is a progressive disease with cycles of muscle degen-
eration and regeneration, the maintained values in areas of col-
lagen in the dogs that underwent physical therapy suggests that 
movement may play an important role in fibrosis adaptation.
ROM and muscle collagen in GRMD model undergoing physical therapy
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Adaptations to exercise in dystrophic muscle are well 
known from other models such as mice, hamsters and rabbits7. 
The main goal of those studies was to elucidate the effect of 
exercise on functional performance and muscle pathology. 
Grange and Call13 suggested that a directed exercise study on 
GRMD dogs would be a good bridge to human studies.
Does motor physical therapy play a positive role in muscle 
flexibility and contractures among muscular dystrophy pa-
tients? How does dystrophic muscle tissue respond to such 
recruitment? Fibrosis seems to provide an insight towards 
understanding this process, because it is the result of repeated 
cycles of muscle degeneration and regeneration in the absence 
of dystrophin. Phenotypic differences, age and routines of daily 
life are important factors that must be considered in muscle 
fibrosis studies because of variability in the progress of the 
disease. 
Conclusion 
The relationship between movement and muscle fibro-
sis deposition is not well known in DMD. Because of the 
similarities in the progression of GRMD and human DMD 
disease, studies using the dog model can provide new insights 
for physical therapy protocols. Therapeutic exercise for mus-
cular dystrophy cases must be well-defined and aim towards 
positively influencing musculoskeletal function with minimal 
muscle fiber deterioration.
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